Cymbalta Superior To SSRIs, Lilly Says; Once-Daily Dosing Not Vital To Uptake
Lilly's pending SNRI Cymbalta induces remission from depression more often than selective serotonin reuptake inhibitors, Exec VP-Science & Technology Steven Paul, MD, said
You may also be interested in...
Lilly is planning to shut down its "Building 105" manufacturing facility in 2004 to make GMP upgrades, CEO Sidney Taurel said during a Dec. 3 analyst dinner in New York
Lilly plans to launch Cymbalta in summer 2004, pending a pre-approval inspection and the build-up of sufficient product inventory
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011